NL-OMON42614已完成不适用
A Phase 1, Single-Time Blood Sample Collection Study for Pharmacogenomic Characterization of Subjects That Previously Received Namilumab and Participated in the Phase 1 PRIORA Study. - PRIORA PGx
Takeda0 个研究点目标入组 4 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 4
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •The participant (or, when applicable, the participant*s legally acceptable representative) voluntarily signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
排除标准
- •-Participants who did not receive namilumab during the PRIORA study.
- •-Participants without any response time point recorded 4-week after the last dose of namilumab and beyond this time point
- •-Participants who were excluded from post-hoc analysis due to protocol violations during the previous PRIORA study.
研究者
相似试验
进行中（未招募）
1 期
Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIEUCTR2007-001377-28-FRMerck Serono International S.A.
进行中（未招募）
不适用
Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIEUCTR2007-001377-28-NLMerck Serono International S.A.92
撤回
4 期
Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with Raptiva (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST).auto-immune diseases1003553410003816thrombocytopeniaNL-OMON32149Serono10
招募中
不适用
Collection of blood samples for the evaluation of the analytical performance of two new in vitro test systems for tuberculosis diagnosticsA15-A19TuberculosisDRKS00027129R-Biopharm AG636
已完成
不适用
Trial for collection of blood samples from healed Covid-19 patients - research and development of in-vitro diagnosticsSARS-CoV-2 infectionCovid-19U07.1COVID-19, virus identifiedDRKS00022406R-Biopharm AG50